Dehydroascorbic Acids-modified Polymer Micelles Target Cancer Cells to Enhance Anti-tumor Efficacy of Paclitaxel

[1]  Chen Jiang,et al.  Cell microenvironment-controlled antitumor drug releasing-nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy. , 2015, ACS applied materials & interfaces.

[2]  Chao Xu,et al.  Crystal structure of the human glucose transporter GLUT1 , 2014, Nature.

[3]  Xinrong Liu,et al.  Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system , 2014, International journal of nanomedicine.

[4]  J. Schellens,et al.  Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review , 2014, Anti-cancer drugs.

[5]  K. Wooley,et al.  Poly(ethylene oxide)‐block‐Polyphosphoester‐graft‐Paclitaxel Conjugates with Acid‐Labile Linkages as a pH‐Sensitive and Functional Nanoscopic Platform for Paclitaxel Delivery , 2014, Advanced healthcare materials.

[6]  S. Ren,et al.  Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy. , 2014, ACS nano.

[7]  Derek S. Chan,et al.  SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice , 2013, Gut.

[8]  Samuel A. Williams,et al.  Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century , 2013, Laboratory Investigation.

[9]  Jianbin Tang,et al.  Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery. , 2013, Biomaterials.

[10]  L. Szablewski.  Expression of glucose transporters in cancers. , 2013, Biochimica et biophysica acta.

[11]  Chen Jiang,et al.  Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. , 2013, ACS nano.

[12]  Amolkumar Karwa,et al.  In vitro efficacy of paclitaxel-loaded dual-responsive shell cross-linked polymer nanoparticles having orthogonally degradable disulfide cross-linked corona and polyester core domains. , 2013, Molecular pharmaceutics.

[13]  P. Pattyn,et al.  Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members , 2012, BMC Cancer.

[14]  Kwangmeyung Kim,et al.  The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles. , 2012, Biomaterials.

[15]  M. Socinski,et al.  Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Gress,et al.  Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid , 2012, Gut.

[17]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[18]  Xian Jiang,et al.  Downregulating hypoxia‐inducible factor‐2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma , 2012, Cancer science.

[19]  Ick Chan Kwon,et al.  Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links. , 2012, Biomaterials.

[20]  Yi Yan Yang,et al.  The use of cholesterol-containing biodegradable block copolymers to exploit hydrophobic interactions for the delivery of anticancer drugs. , 2012, Biomaterials.

[21]  Chaoliang He,et al.  Stimuli‐Sensitive Synthetic Polypeptide‐Based Materials for Drug and Gene Delivery , 2012, Advanced healthcare materials.

[22]  R. Fimmers,et al.  Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). , 2011, European urology.

[23]  Shudong Lin,et al.  Interlayer-crosslinked micelle with partially hydrated core showing reduction and pH dual sensitivity for pinpointed intracellular drug release. , 2011, Angewandte Chemie.

[24]  C. Galbán,et al.  Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. , 2011, Biomaterials.

[25]  K. Lee,et al.  Nanomedicine-nanoemulsion formulation improves safety and efficacy of the anti-cancer drug paclitaxel according to preclinical assessment. , 2011, Journal of nanoscience and nanotechnology.

[26]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[27]  Lin Zhou,et al.  Effects of suppressing glucose transporter-1 by an antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells. , 2011, Hepatobiliary & pancreatic diseases international : HBPD INT.

[28]  J. Bonevich,et al.  Preparation and Properties of Nanoparticles of Calcium Phosphates With Various Ca/P Ratios , 2010, Journal of research of the National Institute of Standards and Technology.

[29]  M. Finn,et al.  Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation. , 2009, Angewandte Chemie.

[30]  C. Hellerbrand,et al.  GLUT1 as a therapeutic target in hepatocellular carcinoma , 2009, Expert opinion on therapeutic targets.

[31]  P. Oefner,et al.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. , 2009, The American journal of pathology.

[32]  M. Tomi,et al.  Dehydroascorbic acid uptake and intracellular ascorbic acid accumulation in cultured Müller glial cells (TR-MUL) , 2008, Neurochemistry International.

[33]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[34]  S. Armes,et al.  Recent Advances in Shell Cross-Linked Micelles , 2007 .

[35]  T. Deming.  Synthetic polypeptides for biomedical applications , 2007 .

[36]  A. Mobasheri,et al.  Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics , 2007, Chemotherapy.

[37]  O. Kwon,et al.  6-Bromo-6-deoxy-l-ascorbic Acid , 2005, Journal of Biological Chemistry.

[38]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[39]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[40]  P. Hruz,et al.  Structural analysis of the GLUT1 facilitative glucose transporter (review). , 2001, Molecular membrane biology.

[41]  T. Yoshikawa,et al.  Expression of facilitative glucose transporter 1 mRNA in colon cancer was not regulated by k-ras. , 2000, Cancer letters.

[42]  F. Lordick.  Gastrointestinal cancer: Over the RAINBOW—renaissance in antiangiogenesis , 2015, Nature Reviews Clinical Oncology.

[43]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. , 2003, Lancet.